Enanta to appeal ruling related to '953 patent infringement lawsuit 07:25 ENTA, PFE Enanta Pharmaceuticals (ENTA) announced that the United States District Court of Massachusetts has issued a ruling on a summary judgment motion filed by Pfizer (PFE) in connection with Enanta's patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 in the manufacture, use and sale of Pfizer's COVID-19 antiviral, Paxlovid. The Court issued a summary judgment decision granting Pfizer's motion that the '953 Patent is invalid. In its decision, the Court also denied Enanta's partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity. Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit.
Enanta price target lowered to $18 from $27 at H.C. Wainwright 06:12 ENTA H.C. Wainwright lowered the firm's price target on Enanta to $18 from $27 and keeps a Buy rating on the shares. Zelicapavir successfully met the virology endpoint of RSVPEDs, a Phase 2 placebo-controlled study of zelicapavir focused on pediatric patients aged 28 days to 36 months with RSV in both hospitalized and nonhospitalized settings, but the firm has "several concerns" on zelicapavir's ability in RSV symptom reduction, the analyst tells investors. Following the report of the top-line dataset from the trial, the firm is reducing its assumed probability of success for zelicapavir in RSV to 50% from 60%.
Read more at:
https://thefly.com/n.php?id=4043306
Read more at:
https://thefly.com/n.php?id=4043329